Silence Therapeutics plc (OTCMKTS:SLNCF) Short Interest Up 351.9% in August

Silence Therapeutics plc (OTCMKTS:SLNCF) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totaling 2,350 shares, an increase of 351.9% from the August 15th total of 520 shares. Based on an average daily trading volume, of 521 shares, the days-to-cover ratio is presently 4.5 days.

Silence Therapeutics Price Performance

Silence Therapeutics stock remained flat at $4.00 during midday trading on Friday. Silence Therapeutics has a one year low of $1.06 and a one year high of $5.99. The company has a 50 day simple moving average of $3.05 and a 200 day simple moving average of $2.28.

About Silence Therapeutics

Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.

The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.